About 200 reports

  • Hypertension Drugs Markets in China
  • Hypertension Drugs Sales Volume

THE HYPERTENSION DRUGS INDUSTRY IS ONE OF KEY SECTORS OF CHINESE INDUSTRY AND HAS BECOME MORE AND MORE IMPORTANT.

  • Hypertension
  • China
  • Demand
  • AstraZeneca China Inc.
  • Sanofi-Synthelabo Inc.
  • Hypertension Drugs Sales Volume
  • Hypertension Drugs Companies in China

THE HYPERTENSION DRUGS INDUSTRY IS ONE OF KEY SECTORS OF CHINESE INDUSTRY AND HAS BECOME MORE AND MORE IMPORTANT.

  • Hypertension
  • China
  • AstraZeneca China Inc.
  • Hangzhou MSD Pharmaceutical Co., Ltd
  • Sanofi-Synthelabo Inc.
  • Other Hypertension Drugs
  • IV. HYPERTENSION DRUGS PRODUCTION AND DEMAND

INTRODUCTION Chapter I Table ##: Economic Outlook Summary (Billion Yuan) Chart ##: Economic Outlook Summary (Billion Yuan) Chapter I INTRODUCTION The current market for Hypertension Drugs in China is growing rapidly.

  • Hypertension
  • China
  • Demand
  • Trade
  • AstraZeneca China Inc.
  • Systemic hypertension
  • PULMONARY ARTERIAL HYPERTENSION KEY METRICS IN THE 7MM

Prognostic factors in pulmonary arterial hypertension with Dana Point group ##.

  • Hypertension
  • United States
  • Forecast
  • Actelion Ltd
  • United Therapeutics Corporation
  • Increase in incidence of pulmonary hypertension (PH)
  • 66 GLOBAL PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET 2017-2021

According to the CDC, ## million Americans have high blood pressure, i. e., one in every three adults have symptoms of PAH.

  • Hypertension
  • Actelion Ltd
  • Daiichi Sankyo Company
  • Novartis AG
  • United Therapeutics Corporation

The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase II, with only one drug in the NDA/ BLA phase.

  • Chronic Disease
  • Hypertension
  • Pathology
  • World
  • Pulmonary Arterial Hypertension: Executive Summary
  • 4.1 BIBLIOGRAPHY

Prognostic factors in pulmonary arterial hypertension with Dana Point group ##.

  • Hypertension
  • Germany
  • Japan
  • United States
  • Forecast

Pulmonary Arterial Hypertension Market Size, Outlook and Growth Opportunities, 2019- 2025 ##.

  • Chronic Disease
  • Hypertension
  • APAC
  • World
  • Market Size
  • Classification of hypertension
  • Prevalence of hypertension, total (000s)

Table ##.

  • Chronic Disease
  • Hypertension
  • Pathology

Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025 CONTENTS ## FORECAST: PULMONARY HYPERTENSION (Published on ## October 2018) ## OVERVIEW ## RECENT FORECAST UPDATES ## MARKET DYNAMICS ## FORECAST AND FUTURE TRENDS ## MARKET DEFINITION AND METHODOLOGY ## PR

  • Chronic Disease
  • Hypertension
  • European Union
  • Japan
  • United States

Systemic Hypertension Market and Forecast Analysis to 2027 CONTENTS ## EPIDEMIOLOGY: SYSTEMIC HYPERTENSION (Published on ## June 2018) ## OVERVIEW ## DISEASE BACKGROUND ## METHODOLOGY ## FORECAST ## BIBLIOGRAPHY ## APPENDIX: ADDITIONAL SOURCES LIST OF FIGURES ## Figure

  • Hypertension
  • European Union
  • Japan
  • United States
  • Forecast

Global Hypertension Epidemiology and Patient Flow Analysis - 2017 ##.

  • Hypertension
  • France
  • United States
  • World
  • Forecast

2018 Idiopathic Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Idiopathic Hypertension Market ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Idiopathic Hypertension Pipeline Analysis

  • Hypertension
  • Pharmaceutical

2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Essential Hypertension Pipeline Analysis ##. ##

  • Hypertension
  • Pharmaceutical

Global Plumonary Arterial Hypertension Epidemiology and Patient Flow Analysis - 2017 ##.

  • Hypertension
  • France
  • United States
  • World
  • Forecast
  • SYSTEMIC HYPERTENSION
  • Overview: Hypertension

PREHYPERTENSION ##-## Less than ## Systolic BP (mm Hg) Diastolic BP (mm Hg) Less than ## ##-## STAGE ## HYPERTENSION STAGE ## HYPERTENSION Greater than or equal to ## Greater than or equal to ## ##-## ##-## CLASSIFICATION OF HYPERTENSION Category NORMAL PATHO

  • Hypertension
  • Actelion Ltd
  • AstraZeneca PLC
  • Daiichi Sankyo Company
  • Sanofi S.A.
  • ANTI-HYPERTENSIVE THERAPEUTICS, TREATMENT ALGORITHM OF HYPERTENSION
  • ANTI-HYPERTENSIVE THERAPEUTICS, GLOBAL, HYPERTENSION PREVALENCE RATE (%),

For example, SER-## is an opioid receptor like-## (ORL-##) agonist that failed in Phase II clinical trial in patients with isolated systolic hypertension.

  • Hypertension
  • Market Size
  • Daiichi Sankyo Company
  • Merck & Co., Inc.
  • Novartis AG
  • Increasing incidence of hypertension coupled with geriatric population
  • monitoring the person's blood pressure accurately. It is highly useful in evaluating white coat hypertension or masked hypertension.

High blood pressure leading to hypertension is one of the primary reason for heart diseases.

  • Blood Device
  • Hemodynamic Monitor
  • Hypertension
  • World
  • Forecast

Europe Hypertension Epidemiology and Patient Flow Analysis - 2017 ##.

  • Hypertension
  • Europe
  • France
  • Germany
  • Forecast

Europe Plumonary Arterial Hypertension Epidemiology and Patient Flow Analysis - 2017 ##.

  • Hypertension
  • Europe
  • France
  • Germany
  • Italy
  • Global pulmonary hypertension market: 2014-2019 ($ billions)
  • Strength

The drug prevents the binding of ET-## to both endothelin receptors, ET- A and B resulting in decreased hypertension.

  • Hypertension
  • United States
  • Actelion Ltd
  • Bayer AG
  • United Therapeutics Corporation

Hypertension Phase ## Clinical Trials, 2016 ##.

  • Hypertension
  • France
  • United States
  • Market Shares
  • Market Size

Pulmonary Hypertension Phase ## Clinical Trials, 2016 ##.

  • Hypertension
  • France
  • United States
  • Market Shares
  • Market Size
  • Increasing incidence of hypertension and growth of geriatric population
  • AMERICAS - MARKET SIZE AND FORECAST 2017-2022

You can easily book an appointment with one online.

  • Blood Device
  • Hypertension
  • World
  • Forecast
  • Omron Corporation
  • Increasing incidence of hypertension coupled with geriatric population
  • Identifying factors impacting market growth

High blood pressure leading to hypertension is one of primary reason for cardiovascular diseases.

  • Hemodynamic Monitor
  • Hypertension
  • World
  • Forecast
  • Omron Corporation

Global Pulmonary Arterial Hypertension Epidemiology and Patient Flow Analysis - 2016 ##.

  • Hypertension
  • France
  • United States
  • World
  • Forecast

esuberaprost

8770 10000 7800

esuberaprost CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## esuberaprost : Pulmonary hypertension LIST OF FIGURES ## Figure ##: Esuberaprost for pulmonary hypertension – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of esuberapro

  • Hypertension
  • Therapy
  • United States

Tyvaso

8770 10000 7800

Tyvaso CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Tyvaso : Pulmonary hypertension LIST OF FIGURES ## Figure ##: Tyvaso for pulmonary hypertension – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Tyvaso for pulmonary

  • Chronic Disease
  • Hypertension
  • Pharmaceutical
  • Therapy
  • United States

INOpulse

8770 10000 7800

INOpulse CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## INOpulse : Pulmonary hypertension LIST OF FIGURES ## Figure ##: INOpulse for pulmonary hypertension – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of INOpulse for pulmonar

  • Chronic Disease
  • Hypertension
  • Therapy
  • United States
  • Market Description

Opsumit

8770 10000 7800

Opsumit CONTENTS ## OVERVIEW ## Drug Overview ## Product Profiles ## Opsumit : Pulmonary hypertension LIST OF FIGURES ## Figure ##: Opsumit for pulmonary hypertension – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of Opsumit for pulmonary

  • Hypertension
  • Therapy
  • European Union
  • Japan
  • United States